Simulations Plus Releases GastroPlus® Version 9.9
January 30 2024 - 8:30AM
Business Wire
New version delivers on FDA collaborations
and user feedback for expansion of non-oral delivery route
models
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemicals, and consumer goods industries, today
announced the release of GastroPlus® 9.9, the latest version of its
flagship physiologically based pharmacokinetics/biopharmaceutics
(PBPK/PBBM) modeling and simulation software.
Key enhancements include:
- Expanded the ocular (OCAT™), oral cavity (OCCAT™), and dermal
(TCAT™) models by adding new formulation and PK/PD mechanisms to
better capture local and systemic exposure levels in animals and
humans
- Extended the ACAT™ model to enhance the evaluation of
formulation approaches for local gastrointestinal (GI) disease
states
- Improved Biologics Module features to mimic study designs and
refine dose optimization simulations for clinical trial
success
- Upgraded with ADMET Predictor® version 11 models, enhancing our
First in Human Simulator
“Our software updates reflect the needs our customers
communicate to us, and GastroPlus 9.9 is no exception,” said Neil
Miller, Vice President of Simulation Sciences at Simulations Plus.
“We incorporated feedback from more than 100 companies into these
latest enhancements, ensuring they truly provide the improved
functionality our customers require. And as we do with every
software release, we also updated our models with the latest
scientific research, leveraging more than 30 peer-reviewed papers
to improve the predictive capabilities of our software
platform.”
“For many years, we have worked on collaborative projects with
the FDA and other regulatory agencies to improve the technology
available to the pharmaceutical industry and increase the safety of
animal and human trials,” said Dr. Haiying Zhou, Sr. Director of
Simulation Technologies at Simulations Plus. “This is one reason
our clients know they can rely on data generated with GastroPlus to
inform their program design and support regulatory submissions. In
GastroPlus 9.9 specifically, our updates to the Additional Dosage
Routes (ADR) Module were built with FDA involvement and funding
from three separate FDA grants, and these enhancements are now
available for the global GastroPlus user community to apply to
their research programs to accelerate the development of new
therapies to help patients worldwide.”
GastroPlus 9.9 is available now for licensing and download.
About Simulations Plus, Inc.
Serving clients worldwide for more than 25 years, Simulations
Plus is a leading provider in the biosimulation market providing
software and consulting services supporting drug discovery,
development, research, and regulatory submissions. We offer
solutions that bridge artificial intelligence (AI)/machine
learning, physiologically based pharmacokinetics, quantitative
systems pharmacology/toxicology, and population PK/PD modeling
approaches. Our technology is licensed and applied by major
pharmaceutical, biotechnology, and regulatory agencies worldwide.
For more information, visit our website at
www.simulations-plus.com. Follow us on LinkedIn | Twitter |
YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our website to read
our 2022 ESG update.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240130518804/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Lisa Fortuna
310-622-8251 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2024 to May 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From May 2023 to May 2024